Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAIS Birch-Alder sublingual immunotherapy for tree pollen-induced allergic rhinoconjunctivitis
2013-002129-43Phase 3Completed
- Sponsor
- Lofarma S.p.A.
- Start
- Aug 2013
- Countries
- 1
01
Overview
Phase 3 trial of LAIS Birch-Alder tablets in allergic rhinoconjunctivitis (ARC) and allergic rhinitis (AR), sponsored by Lofarma S.p.A. Primary endpoints: Total Combined Score during peak birch pollen season, Total Combined Score over 30-day birch pollen season and 3 more. Started Aug 2013; status: completed.
02
Drugs
LAIS Birch-Alder tablets
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic rhinitis (AR)
Beyond the preview
Go deeper on 2013-002129-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002129-43.